Effect of antiviral therapy in reducing perinatal transmission of hepatitis B virus and maternal outcomes after discontinuing them
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: There have been numerous efforts to reduce mother-to-child transmission (MTCT) of hepatitis B virus (HBV) with antiviral agents during pregnancy. However, there are limited data regarding the outcomes of pregnant women after delivery. This study was performed to evaluate the efficacy of antiviral agents in preventing MTCT of HBV and maternal long-term outcomes. Methods: The HBV-infected pregnant women treated with antiviral agents to prevent MTCT were retrospectively reviewed. Forty-one pregnant women who received telbivudine or tenofovir during late pregnancy (28-34 week) were analyzed. Hepatitis B virus surface antibody (HBsAb) positivity was tested in 43 infants after 7 months of birth. Eleven mothers were followed >1 year after delivery. Results: The mean HBV DNA titer before antiviral therapy was 8.67 (6.60–9.49) log copies/mL, and the median age at delivery was 32 years (range, 22–40). Eleven patients were treated with tenofovir and 30 with telbivudine. The median duration was 57 days (range, 23–100), and the median HBV DNA titer at birth was 5.06 log copies/mL (range, 2.06–6.50). Antiviral treatments were associated with significant HBV DNA reduction (P<0.001). Among 43 infants (two cases of twins), HBsAb was not detected in two, subsequently confirmed to have HBV infection. Biochemical flare was observed in two of 11 mothers followed >12 months, and an antiviral agent was administered. Conclusions: Antiviral treatment during late pregnancy effectively reduced MTCT. Long-term follow-up should be required in such cases. In addition, given that maternal biochemical flare occurred in 18% of mothers, re-administration of antiviral agents might be required.
Abstract
Background/Aims: There have been numerous efforts to reduce mother-to-child transmission (MTCT) of hepatitis B virus (HBV) with antiviral agents during pregnancy. However, there are limited data regarding the outcomes of pregnant women after delivery. This study was performed to evaluate the efficacy of antiviral agents in preventing MTCT of HBV and maternal long-term outcomes. Methods: The HBV-infected pregnant women treated with antiviral agents to prevent MTCT were retrospectively reviewed. Forty-one pregnant women who received telbivudine or tenofovir during late pregnancy (28-34 week) were analyzed. Hepatitis B virus surface antibody (HBsAb) positivity was tested in 43 infants after 7 months of birth. Eleven mothers were followed >1 year after delivery. Results: The mean HBV DNA titer before antiviral therapy was 8.67 (6.60–9.49) log copies/mL, and the median age at delivery was 32 years (range, 22–40). Eleven patients were treated with tenofovir and 30 with telbivudine. The median duration was 57 days (range, 23–100), and the median HBV DNA titer at birth was 5.06 log copies/mL (range, 2.06–6.50). Antiviral treatments were associated with significant HBV DNA reduction (P<0.001). Among 43 infants (two cases of twins), HBsAb was not detected in two, subsequently confirmed to have HBV infection. Biochemical flare was observed in two of 11 mothers followed >12 months, and an antiviral agent was administered. Conclusions: Antiviral treatment during late pregnancy effectively reduced MTCT. Long-term follow-up should be required in such cases. In addition, given that maternal biochemical flare occurred in 18% of mothers, re-administration of antiviral agents might be required.
참고문헌 (20)
- Visvanathan K, "Managing HBV in pregnancy. Prevention, prophylaxis, treatment and follow-up: position paper produced by Australian, UK and New Zealand key opinion leaders", Gut, 65, pp.340~350 (2016)
- Yogeswaran K, "Chronic hepatitis B in pregnancy : unique challenges and opportunities", Korean J Hepatol, 17, pp.1~8 (2011)
- GBD 2013 Mortality, "Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013", Lancet, 385, pp.117~171 (2015)
- Stevens CE, "HBeAg and anti-HBe detection by radioimmunoassay : correlation with vertical transmission of hepatitis B virus in Taiwan", J Med Virol, 3, pp.237~241 (1979)
- Wen WH, "Motherto-infant transmission of hepatitis B virus infection : significance of maternal viral load and strategies for intervention", J Hepatol, 59, pp.24~30 (2013)
- Terrault NA, "AASLD guidelines for treatment of chronic hepatitis B", Hepatology, 63, pp.261~283 (2016)
- 김혁, "Recent trends in hepatitis B virus infection in the general Korean population", The Korean Journal of Internal Medicine, 28(4), pp.413~419 (2013), 대한내과학회[DOI]
- World Health Organization, "Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection", World Health Organization, 89~93 (2015)
- Zou H, "Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers", J Viral Hepat, 19, pp.e18~e25 (2012)
- Brown RS Jr, "Antiviral therapy in chronic hepatitis B viral infection during pregnancy : a systematic review and meta-analysis", Hepatology, 63, pp.319~333 (2016)
- Leung NW, "Early viral kinetics with telbivudine, tenofovir or combination of both in immunotolerant patients with hepatitis B e antigen-positive chronic hepatitis B", Infect Dis Ther, 3, pp.191~202 (2014)
- Chen HL, "Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus", Hepatology, 62, pp.375~386 (2015)
- Greenup AJ, "Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus", J Hepatol, 61, pp.502~507 (2014)
- Cheung KW, "Towards complete eradication of hepatitis B infection from perinatal transmission : review of the mechanisms of in utero infection and the use of antiviral treatment during pregnancy", Eur J Obstet Gynecol Reprod Biol, 169, pp.17~23 (2013)
- Yang FS, "Prevention of peripartum hepatitis B transmission", N Engl J Med, 375, pp.1497~ (2016)
- Pan CQ, "Cesarean section reduces perinatal transmission of hepatitis B virus infection from hepatitis B surface antigen-positive women to their infants", Clin Gastroenterol Hepatol, 11, pp.1349~1355 (2013)
- Yi P, "Management of mother-tochild transmission of hepatitis B virus : propositions and challenges", J Clin Virol, 77, pp.32~39 (2016)
- Navabakhsh B, "Hepatitis B virus infection during pregnancy : transmission and prevention", Middle East J Dig Dis, 3, pp.92~102 (2011)
- Yoon JH, "Association of HLA alleles with the responsiveness to hepatitis B virus vaccination in Korean infants", Vaccine, 32, pp.5638~5644 (2014)
- Hu Y, "Virological determinants of spontaneous postpartum e antigen seroconversion and surface antigen seroclearance in pregnant women infected with hepatitis B virus", Arch Med Res, 47, pp.207~213 (2016)